26 May, 2017
The stock closed its day at $6.95.
Glenmede Trust Na invested in 33,907 shares. Pepsico Inc now has $165.81 billion valuation. The lowest price the stock reached in the last trading day was $1.16 and compares with the $1.03 52-week low. About shares traded. PepsiCo, Inc. Altisource Asset Management Corp (AAMC) has risen 495.14% since May 24, 2016 and is uptrending. It has underperformed by 4.50% the S&P500.
Among 4 analysts covering Progenics Pharm (NASDAQ:PGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The company was maintained on Friday, August 7 by Needham. "(PGNX) Stock Rating Reaffirmed by Needham & Company LLC" was reported by Transcript Daily and is the property of of Transcript Daily. The MF Rank of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 4.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The stock presently has an average rating of Buy and a consensus price target of $11.29. See Progenics Pharmaceuticals, Inc.
In taking a look at some other notable technicals, Progenics Pharmaceuticals, Inc. The company has market cap of $144.99 million. The Company's pipeline includes therapeutic agents created to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
P/E ratio of the company is 66.06. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation.
Investors sentiment increased to 1.22 in Q4 2016. The ROIC 5 year average is -1.500120 and the ROIC Quality ratio is -0.761599. Cadence Capital Management Llc sold 121,751 shares as Progenics Pharmaceuticals In (PGNX)'s stock declined 34.18%. 31 funds opened positions while 30 raised stakes. "As long as the US economy remains in a good foundation...that creates a supportive environment for equities", said Shannon Saccocia, head of asset allocation and portfolio strategy at Boston Private Wealth, The Wall Street Journal reported. Hsbc Public Limited reported 0% in Progenics Pharmaceuticals, Inc.
10/04/2016 - Brean Capital began new coverage on Progenics Pharmaceuticals Inc. giving the company a " rating. (NASDAQ:PGNX) or 6,367 shares. Bancorp Of Mellon accumulated 571,661 shares. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.07.
11/08/2016 - Progenics Pharmaceuticals Inc. had its " rating reiterated by analysts at Aegis Capital. (NASDAQ:PGNX) for 18,890 shares. Gotham Asset Mgmt Ltd Llc has invested 0.06% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Duncker Streett And invested in 14,718 shares or 0.04% of the stock. Westwood Corporation Il holds 12,000 shares or 0.02% of its portfolio. Alliancebernstein Lp reported 0% stake. The Q.i. Value of Progenics Pharmaceuticals, Inc.is 56.00000. On the other end, a stock with a score from 0-2 would be viewed as weak. Needham upgraded Progenics Pharmaceuticals, Inc. It has outperformed by 31.71% the S&P500. Broadfin Capital Lc owns 8.95M shares.
Since February 17, 2017, it had 0 insider buys, and 9 selling transactions for $32.14 million activity. $466,265 worth of PepsiCo, Inc. Its down 2.26% from 7.98M shares previously. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. UBS maintained PepsiCo, Inc. The company was downgraded on Friday, August 7 by Zacks. (NASDAQ:PGNX) rating on Friday, October 23. (NYSE:PEP) earned "Hold" rating by S&P Research on Wednesday, October 7. The stock's market capitalization is 482.45M. Jefferies has "Buy" rating and $9 target. Deutsche Bank has "Buy" rating and $120 target.
(NASDAQ:PGNX) latest ratings and price target changes.
